Something new in the treatment arsenal?
AstraZeneca reported positive results from a Phase 3 trial for a breast- cancer treatment, sending its American depositary receipts higher.
Shares of AstraZeneca (ticker: AZN) were up 1.7% to $68.16 in morning trading.
The company said the trial showed that the treatment, datopotamab deruxtecan, showed a significant improvement relative to chemotherapy in terms of progression-free survival. Plans to submit the drug for regulatory approval globally are underway.
Progression-free survival “is defined as the time from random assignment in a clinical trial to disease progression or death from any cause,” according to the National Library of Medicine.